Abstract
Introduction
Compared with many other disease areas (e.g., cancer, immune diseases), the
costs of drug therapy for psychiatric disorders are relatively modest.
However, the World Health Organization forecasts that by 2020, depression-just
one of a spectrum of psychiatric disorders-will be the second most frequent
cause of death and disability in the world and the leading cause in
industrialized nations. In anticipation of this surge, payers in the major
pharmaceutical markets would like to exercise greater control over the use of
psychiatric drugs.
Get the Answers You Need to Shape Your Strategy
In just the major pharmaceutical markets, the number of people affl icted with
common psychiatric disorders will increase, and spending on drug therapies
will grow steadily. How will payers try to curb spending on psychiatric
drugs? The prices of generic antidepressants are much higher in Europe
than in the United States. What factors are behind this differential?
Pharmacy benefits offered by U.S. private insurers tend to be considerably
more generous than the coverage provided by Medicare and Medicaid, but
cost-containment measures are proliferating. What steps are private
insurers taking to control drug expenditures? Medicare Part D offers
outpatient drug coverage to all Medicare beneficiaries who choose to enroll.
What will be the standard benefi t design of Part D in 2007? The U.S.
Medicaid program is a major source of funding for psychiatric drugs-especially
atypical antipsychotics. What cost-cutting measures are state Medicaid
programs instituting to control drug expenditures? France has the lowest
average prices of any of the major pharmaceutical markets for branded
antidepressants. Nevertheless, the government would like to reduce spending on
this drug class. What steps has the Caisse Nationale de l' Assurance Maladie
taken to stimulate France' s relatively immature generics market? How
successful have these measures been so far?
Scope
- Drug classes covered: antidepressants, antipsychotics,
psychostimulants, hypnotics, sedatives, and anxiolytics.
- Markets covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Price comparisons: comparisons of international pricing of the
psychiatric drug classes in this report.
- Reimbursement: overview of the general environment in each market
and analysis of factors specific to individual psychiatric drug classes.
- Market outlook: pricing and reimbursement implications for the
manufacturers of psychiatric drugs.
Mentioned in This Spectrum Report
View Cart
